Incyte reports tafasitamab combo benefit in Phase III frontMIND study

Incyte has reported that its pivotal Phase III frontMIND study showed benefits when tafasitamab was combined with lenalidomide and R-CHOP for DLBCL or HGBL. The trial compared Tafa-Len-R-CHOP to R-CHOP alone, the current standard of care, for efficacy and safety. The trial data demonstrated a 25% reduction in risk of disease progression or death with Tafa-Len-R-CHOP versus R-CHOP. Credit: MrWinn / Shutterstock.com. Incyte has reported that its pivotal Phase III frontMIND study showed benefits when Monjuvi / Minjuvi (tafasitamab) was combined with lenalidomide and R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; Tafa-Len-R-CHOP) to treat high-risk diffuse large B-cell lymphoma (DLBCL)…

Source: Clinical Trials Arena